SEMA4D: Semaphorin-4D
Cell surface receptor for PLXNB1 and PLXNB2 that plays an important role in cell-cell signaling.
- Drugs that act on it: 1
- Approved: 0
- In phases 1 to 3: 1
- Sponsors: 1
Who is on it, and how far along
Every drug ChEMBL records acting on SEMA4D, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Antibody 1
| Trial of Immunotherapy With Avelumab and Pepinemab As Second Line For Patients With Metastatic Pancreatic Adenocarcinoma | Pepinemab | Phase 1 / Phase 2 | Active, not recruiting | Vaccinex Inc. | Nov 1, 2021 |
| VX15/2503 With or Without Ipilimumab and/or Nivolumab in Patients With Resectable Stage IIIB-D Melanoma | Pepinemab | Phase 1 | Active, not recruiting | Emory University | Dec 7, 2018 |
| VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck Cancer | Pepinemab | Phase 1 | Active, not recruiting | Emory University | Oct 1, 2018 |
- Skin aging0.44
- Sclerosing cholangitis0.37
- Intelligence0.28
- Placental abruption0.19
- Otosclerosis0.15
- Neoplasm0.13
- Huntington disease0.11
- Head and neck squamous cell carcinoma0.10
- Rheumatoid arthritis0.10
- Melanoma0.10
- Acute myeloid leukemia0.10
- Acute lymphoblastic leukemia0.10
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL4630887, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt Q92854, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets